Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/daclatasvir for hospitalized adults with COVID-19
IRCT20200624047908N1Phase 3Completed
- Sponsor
- Abadan University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Standard protocol + sofosbuvir/daclatasvir with Standard protocol + placebo (2 arms). Primary endpoint: Recovery within 10 days since the start of taking medicine. Started Jul 2020; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200624047908N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200624047908N1.